Biotek-snakken — April 2022
-
Roche får forlomme til coronamiddel hos FDA https://proinvestor.com/investornyt/804151/roche-far-forlomme-til-coronamiddel-hos-fda
-
Bioporto ser øget driftsunderskud i 2022 https://proinvestor.com/investornyt/805258/bioporto-ser-oget-driftsunderskud-i-2022
-
These COVID Stocks Will Be Incredibly Profitable https://www.proinvestor.com/investornyt/806965/these-covid-stocks-will-be-incredibly-profitable
-
Orphazyme siger farvel til medstifter og forskningschef https://proinvestor.com/investornyt/807291/orphazyme-siger-farvel-til-medstifter-og-forskningschef
-
3 Biotech Stocks That Could Help Make You a Fortune https://www.proinvestor.com/investornyt/808715/3-biotech-stocks-that-could-help-make-you-a-fortune
-
Best Biotech Stocks To Buy Now? 5 To Know https://www.proinvestor.com/investornyt/809078/best-biotech-stocks-to-buy-now-5-to-know
-
JohnW og LP90 er stadig i Zymes ligeså, men tror den får svært ved at komme tilbage til gamle niveauer. Der er nok røget for meget tillid down the drain. Der er en del triggere i løbet af året, så bestemt mulighed for at der kan rykkes en del i kursniveauet. Ny ADC platform præsenteres snarest og trispecifik platform sidst på året. Desuden tre abstracts på ASCO formentlig, hvor specielt opfølgende data på first Line GEA bliver vigtige, så vi ser hvad tislelizumab bidrager med
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind